Bausch Agrees $300m Glumetza Antitrust Settlement As Lupin Awaits Trial
Lupin Set To Face Trial Over Allegations In October 2021
Bausch Health, which rebranded from Valeant Pharmaceuticals following a list of controversies, has reached a proposed settlement deal worth $300m to resolve claims it paid off ANDA sponsor Lupin to delay generic entry for a generic to its Glumetza brand, paving the way for an extraordinary price hike.
You may also be interested in...
Philip Morris once again pledged to up R&D in Vectura after its £1.1bn takeover offer for the UK-based inhalation specialist became unconditional, following the tobacco giant’s acrimonious face-off with private equity Carlyle earlier this year.
Lupin has agreed to pay $248m to settle the majority of antitrust claims against the company alleging that it caused and enabled the prolonged delayed launch of generic Glumetza, which subsequently saw a price hike of more than 800% by originator Valeant, now Bausch Health.
Ahead of launching potentially its Lucentis biosimilar in the EU early next year, Samsung Bioepis has reported two lots of positive analysis involving its Byooviz biosimilar, at the same time as it disclosed the findings of a five-year follow-up study for its trastuzumab biosimilar, Ontruzant.